Northwest & Ethical Investments L.P. decreased its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 47.8% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 39,313 shares of the medical research company's stock after selling 35,995 shares during the period. Northwest & Ethical Investments L.P.'s holdings in Edwards Lifesciences were worth $2,849,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in EW. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $266,000. Bank Pictet & Cie Europe AG raised its holdings in shares of Edwards Lifesciences by 16.7% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company's stock valued at $757,000 after acquiring an additional 1,463 shares in the last quarter. Townsquare Capital LLC raised its holdings in shares of Edwards Lifesciences by 24.8% in the 4th quarter. Townsquare Capital LLC now owns 6,501 shares of the medical research company's stock valued at $481,000 after acquiring an additional 1,293 shares in the last quarter. CreativeOne Wealth LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $201,000. Finally, GeoWealth Management LLC raised its holdings in shares of Edwards Lifesciences by 65.5% in the 4th quarter. GeoWealth Management LLC now owns 1,897 shares of the medical research company's stock valued at $140,000 after acquiring an additional 751 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company's stock.
Edwards Lifesciences Price Performance
NYSE:EW traded up $0.5950 during mid-day trading on Friday, reaching $81.7550. The stock had a trading volume of 3,076,141 shares, compared to its average volume of 4,824,093. The firm has a 50 day moving average price of $77.58 and a two-hundred day moving average price of $74.69. The stock has a market capitalization of $48.00 billion, a P/E ratio of 11.76, a P/E/G ratio of 3.95 and a beta of 1.08. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68.
Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences's quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.
Analyst Ratings Changes
Several analysts have weighed in on EW shares. Dbs Bank raised Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. Royal Bank Of Canada raised their price target on Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Mizuho raised their price target on Edwards Lifesciences from $87.00 to $95.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Argus raised Edwards Lifesciences to a "strong-buy" rating in a report on Thursday, July 10th. Finally, Stifel Nicolaus boosted their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $85.90.
Read Our Latest Stock Analysis on Edwards Lifesciences
Insiders Place Their Bets
In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 2,570 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $77.40, for a total value of $198,918.00. Following the completion of the transaction, the vice president directly owned 50,356 shares in the company, valued at $3,897,554.40. This trade represents a 4.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,584 shares of company stock valued at $1,897,762 in the last ninety days. Company insiders own 1.29% of the company's stock.
About Edwards Lifesciences
(
Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
See Also

Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.